KACTUS to exhibit at Antibody Engineering & Therapeutics Europe 2024

By Yujiao Zhang

Find us at Booth #23

We will be showcasing our products and services at the Antibody Engineering & Therapeutics (AET) Europe event from June 4th to 6th, 2024. The event will take place at the Excel London Platinum Suite in London, United Kingdom. You can meet and chat with one of our team members at booth #23 to learn more about our library of over 100 VLP/nanodisc-displayed GPCRsFc ReceptorsADC Target Proteins, and many other target proteins for antibody drug discovery.

Need MHC complexes? Check out our 150+ MHC monomers and tetramers for immunotherapy research. Poster #43 is available with more information.

#43: Transforming Tumor Research - Engineering MHCs as Versatile Reagents

When dealing with solid tumors lacking specific biomarkers, the effectiveness of adoptive T cell therapy using TCR-T treatments is limited. We believe that the absence of dependable, multifaceted MHC reagents has been a hindrance in the research and development of treatments for solid tumors. To address this unmet need, we have engineered MHC molecules in several formats with diverse applications and high stability. These improved, highly active MHC molecules have the potential to facilitate solid tumor research and development.

Interested in our 100+ VLP/nanodisc-displayed GPCR library? Check out our poster #44 there!

#44: GPCR VLPs & Nanodiscs for Drug Discovery 

G protein-coupled receptors (GPCRs), also known as seven-transmembrane receptors, represent the most important class of drug targets. However, extraction and purification of membrane proteins like GPCRs, ion channels, and transporters are generally challenging due to low expression levels and the hydrophobic nature of transmembrane segments. To tackle this challenge, we have engineered and produced GPCRs in VLP and/or nanodisc formats, which have been successfully applied to GPCR antibody drug discovery and various in vitro assays.

What is AET?

The AET Europe conference is organized by the antibody society and is considered as Europe's leading event for accelerating next-generation antibodies to achieve commercial success. The conference covers the latest developments in Fc Engineering, Novel Approaches to Antibody Discovery, Multispecific Antibodies, Agonists, Conditionally Active Biotherapeutics, ADCs, Degraders, Theranostics, and more.


Event Details

What: Antibody Engineering & Therapeutics Europe

When: 4 - 6 June, 2024

Where: Excel London Platinum Suite, London, United Kingdom

Booth: #23



KACTUS excels in crafting and producing an array of superior-grade, highly active recombinant proteins and enzymes, catering to diverse sectors like antibody drug discovery, immunotherapy, gene therapy, and mRNA therapeutics. Our expansive catalog, boasting over 3000 recombinant proteins, encompasses a wide spectrum of targets, species, tags, and labels, each thoughtfully chosen to address the specific, unmet needs of scientists engaged in drug development. The hallmark of our product selection process is a rigorous emphasis on exceptional quality and a steadfast commitment to ensuring reliable supply, thereby upholding the highest standards of excellence and client satisfaction.

More information? Contact support@kactusbio.us